InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Comments on India’s draft biotech patent guidelines posted

Peter Leung, Hong Kong


The India Patent Office has released public feedback to its draft guidelines for the examination of biotechnology patents

The guidelines were released on December 11 2013 with a public comment period until January 11. The Patent Office received comments from Indian biotechnology firms, patent law firms, and groups such as the Organisation of Pharmaceuticals Producers of India (OPPO), the Biotechnology Industry Organization (BIO) and even the Japan Intellectual Property...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Just been interviewing Fred Reinhart, president of @AUTM_Network V interesting chat about open innovation - will be on the site next week

Jun 30 2015 05:05 ·  reply ·  retweet ·  favourite
ManagingIP profile

New EU General Court rules effective tomorrow http://t.co/asyjufhrs9 More info here ($/trial) http://t.co/0P9ESxFke4 Imp't for OHIM appeals

Jun 30 2015 03:51 ·  reply ·  retweet ·  favourite
ManagingIP profile

Why biotechs may prefer trade secrets to patents - @mdloney reports from #BIO2015 http://t.co/n7MyHccpab ($/trial) http://t.co/8cTcxSHj9M

Jun 30 2015 02:04 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements